Are PSP patients included in clinical trials representative of the general PSP population?

Progressive supranuclear palsy (PSP) is a rare parkinsonian syndrome with a wide spectrum of clinical presentations. Recently, the MDS published revised diagnosis criteria to provide early and reliable diagnosis of PSP and its variants. Two large randomized clinical trials were initiated in 2017, but the question remains regarding the extrapolation of their results to the general PSP population.

Source: Parkinsonism and Related Disorders - July 9, 2019 Category: Neurology Authors: Louise-Laure Mariani, Raquel Guimar ães-Costa, David Grabli, Benjamin Le Toullec, Florence Cormier-Dequaire, Bertrand Degos, Bruno Dubois, Marie Vidailhet, Lucette Lacomblez, Jean-Christophe Corvol Tags: Short communication Source Type: research